About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ALDR
- Previous Close: $22.45
- 50 Day Moving Average: $22.013
- 200 Day Moving Average: $26.740
- 52-Week Range: $15.82 - $36.48
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.63
- P/E Growth: -0.320
- Market Cap: $1.09B
- Outstanding Shares: 50,296,000
- Beta: 2.61
- Return on Equity: -32.77%
- Return on Assets: -31.60%
Companies Related to Alder BioPharmaceuticals:
- Current Ratio: 25.55%
- Quick Ratio: 25.50%
What is Alder BioPharmaceuticals' stock symbol?
Alder BioPharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."
Where is Alder BioPharmaceuticals' stock going? Where will Alder BioPharmaceuticals' stock price be in 2017?
9 brokerages have issued twelve-month price targets for Alder BioPharmaceuticals' shares. Their predictions range from $38.00 to $47.00. On average, they anticipate Alder BioPharmaceuticals' stock price to reach $42.50 in the next year.
When will Alder BioPharmaceuticals announce their earnings?
Alder BioPharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.
What are analysts saying about Alder BioPharmaceuticals stock?
Here are some recent quotes from research analysts about Alder BioPharmaceuticals stock:
According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (2/16/2017)
Brean Capital analysts commented, "We anticipate ALD403 US drug sales reaching $1 billion annually well before patent expiration in 2032," analyst Difei Yang wrote in a note.Yang noted that the ALD403 has huge market potential as recent data from Migraine Research Foundation says each year in the United States about 10 million to 14 million adults experience frequent or chronic migraines, leading to nearly $13 billion in lost productivity in the United States alone."A primary advantage of ALDR403 vs. other close-to-market CGRP's is its dosing schedule, which consists of a single IV treatment every 3 months. The remaining 3 CGRP's in late-stage development rely on monthly subcutaneous injections," (9/30/2016)
Who owns Alder BioPharmaceuticals stock?
Alder BioPharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (14.93%), Janus Capital Management LLC (9.82%), State Street Corp (3.50%), Foresite Capital Management III LLC (3.24%), Foresite Capital Management II LLC (1.98%) and Brown Advisory Inc. (0.99%). Company insiders that own Alder BioPharmaceuticals stock include Clay B Siegall, Jeffrey T L Smith, John A Latham, Larry Benedict, Mark James Litton, Randall C Schatzman and Stephen M Dow.
Who sold Alder BioPharmaceuticals stock? Who is selling Alder BioPharmaceuticals stock?
Alder BioPharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Highland Capital Management LP, Allianz Asset Management AG, Fiera Capital Corp, FMR LLC and Franklin Resources Inc.. Company insiders that have sold Alder BioPharmaceuticals stock in the last year include Jeffrey T L Smith, John A Latham, Mark James Litton and Randall C Schatzman.
Who bought Alder BioPharmaceuticals stock? Who is buying Alder BioPharmaceuticals stock?
Alder BioPharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Janus Capital Management LLC, Clough Capital Partners L P, State Street Corp, New Leaf Venture Partners L.L.C., Eventide Asset Management LLC, Foresite Capital Management II LLC and Paulson & CO. Inc..
How do I buy Alder BioPharmaceuticals stock?
Shares of Alder BioPharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Alder BioPharmaceuticals stock cost?
One share of Alder BioPharmaceuticals stock can currently be purchased for approximately $21.75.